← FDA DRUG APPROVALS

FDA ANDA · ANDA077162

SERTRALINE HYDROCHLORIDE

Sponsor: CHARTWELL MOLECULAR

APPLICATION
ANDA077162
TYPE
ANDA
ORIGINAL APPROVAL
2007-02-06
LATEST ACTION
2020-02-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval), Discontinued

Products

SERTRALINE HYDROCHLORIDENone (Tentative Approval)
SERTRALINE HYDROCHLORIDE 200MG · TABLET · ORAL
SERTRALINE HYDROCHLORIDEDiscontinued
SERTRALINE HYDROCHLORIDE EQ 100MG BASE · TABLET · ORAL
SERTRALINE HYDROCHLORIDEDiscontinued
SERTRALINE HYDROCHLORIDE EQ 25MG BASE · TABLET · ORAL
SERTRALINE HYDROCHLORIDENone (Tentative Approval)
SERTRALINE HYDROCHLORIDE 150MG · TABLET · ORAL
SERTRALINE HYDROCHLORIDEDiscontinued
SERTRALINE HYDROCHLORIDE EQ 50MG BASE · TABLET · ORAL

Approval history

2020-02-14Labeling · Supplement 9 · standardAP
2020-02-14Labeling · Supplement 7 · standardAP
2020-02-14Labeling · Supplement 8 · standardAP
2016-02-01Labeling · Supplement 5 · standardAP
2014-11-10Labeling · Supplement 4 · standardAP
2008-05-07Labeling · Supplement 3AP
2007-07-12Labeling · Supplement 1AP
2007-07-12Labeling · Supplement 2AP
2007-02-06OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →